预约演示
更新于：2025-04-11
Trinitrate
三硝酸酯
更新于：2025-04-11
概要
基本信息
简介三硝酸酯是默克公司研制的一种小分子药物，于 1983 年首次进入医药市场。该药物具有双重属性：它可作为可溶性鸟苷酸环化酶 (sGC) 的催化剂，以及一氧化氮供体。硝酸甘油的适用范围广泛，包括心绞痛、勃起功能障碍、疼痛和肛裂。通过激发 sGC 刺激和释放一氧化氮，这种多用途药物会导致血管舒张，最终缓解上述疾病。 |
药物类型 小分子化药 |
别名 1,2,3-propanetrioltrinitrate、1,2,3-propanetriyl nitrate、Anrecta + [43] |
靶点 |
作用方式 刺激剂、供体 |
作用机制 ALDH2刺激剂(乙醛脱氢酶刺激剂)、一氧化氮供体 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS号55-63-0 |
关联
304
项与 三硝酸酯 相关的临床试验NCT06859554
Assessing the Therapeutic Efficacy and Safety Profile of Glyceryl Trinitrate (GTN) and Nifedipine Ointments in Acute Anal Fissure Treatment: a Parallel-arm Clinical Trial
CTR20250093
评估受试制剂硝酸甘油舌下片（规格：0.6 mg）与参比制剂Nitrostat®（规格：0.6 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性研究
NCT06785337
"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
100 项与 三硝酸酯 相关的临床结果
登录后查看更多信息
100 项与 三硝酸酯 相关的转化医学
登录后查看更多信息
100 项与 三硝酸酯 相关的专利（医药）
登录后查看更多信息
20,890
项与 三硝酸酯 相关的文献（医药）2025-12-01Techniques in Coloproctology
The use of a methylene blue and glyceryl trinitrate-based cream for the treatment of chronic anal fissures: a phase II randomized pilot trial from a referral coloproctological unit
Article
作者: Laforgia, R ; Lobascio, P ; Pezzolla, A ; Tomasicchio, G ; Cassetta, N ; Altomare, D F ; Gallo, G
BACKGROUND:
Chronic anal fissures (CAFs) are the second most common anorectal disease. Non-surgical treatment includes several options with controversial efficacy. The aim of this study was to evaluate the efficacy and safety of a new ointment based on methylene blue in addition to glyceryl trinitrate.
METHODS:
A phase II randomized single-centre triple-blinded study was carried out in a tertiary proctology unit on patients with CAF. The enrollment started after local ethics committee approval (study n. 6461, protocol approval n. 0045085). Eligible consecutive patients were randomized to one of three different groups, each receiving a different ointment. The efficacy of the treatment was evaluated with the REALISE score.
RESULTS:
Nine patients were treated with cream A (median age 47 years, IQR 40-56, 22% female), nine with cream B (median age 52 years, IQR 49-57, 33% female), and nine with cream C (median age 58 years, IQR 46-62, 55% female). In group A, REALISE scores decreased significantly from a median of 22 (IQR 12-25) to 6 (IQR 4-8) (p < 0.05) after 40 days. In group B, REALISE scores improved significantly from a median of 20 (IQR 17-22) to 5 (IQR 4-9) (p < 0.05). In group C, REALISE scores decreased significantly from a median of 19 (IQR 19-20) to 4 (4-5) (p < 0.05). No statistically differences were recorded. The healing rate was 77% with creams A and C, while it was 44% with cream B.
CONCLUSION:
Methylene blue-based ointments could be a new and innovative treatment for the non-operative management and healing of CAFs.
2025-08-01TISSUE & CELL
Intracellular alterations, vacuolization and bypass mechanism by SARS-CoV-2 infection could be the possible basis of respiratory distress and hypoxia
Article
作者: Khaneja, Poorna ; Joshi, Vinod ; Buvvaji, Shareef Mohammed ; Angel, Bennet ; Joshi, Ramesh ; Angel, Annette
Severe Acute Respiratory Syndrome Coronavirus-2 causes mild to severe Acute Respiratory Distress Syndrome, Pneumonia and lung tissue damage. This leads to sub performance in the pulmonary gaseous exchange by the alveolar cells causing hypoxia associated with clinical severities/mortality. The exact cellular basis of the pulmonary malfunction resulting into death of approximately 7.1 million people needs to be fully studied. Understanding the intracellular alterations in pulmonary cells caused by viral infection could prove to be a significant step in our attempts to revert the respiratory efficiency of the patients through appropriate therapeutic interventions. We have undertaken In-Vitro studies to understand the pathogenesis of SARS-CoV-2 in alveoli. We cultured the Alveolar Epithelium (A549 and L-132), Fibroblasts (WI-38), Human Pulmonary Artery Endothelial Cells (HPAEC-c), and African Green Monkey Kidney Epithelial Cells (Vero-E6) and infected them with SARS-CoV-2. Vacuoles in infected Alveolar Type-2 cells, cytoskeletal deformation, fragmentation of mitochondria in alveolar and arterial endothelial cells, loss of glycoclayx in endothelial cells and a unique bypass exit mechanism of virus were observed as major intracellular changes due to infection. The bypass exit of the daughter virions from lung cells along with loss of glycoclayx due to virus overburdening is reported as mechanism of propagation of infection towards multiple organs. We report that formation of numerous vacuoles in infected Alveolar Type-2 cells and the SARS-CoV-2 virions occupying these vacuoles could hamper the trans cytoplasmic trafficking of surfactant mixed inspired air and its subsequent transfer into venous blood through cell membranes of Alveolar Type -2 Cells and Capillary Wall Cells of pulmonary vein. The possible use of repurposed Nitroglycerine based drug to retrieve required intracellular cytoplasmic viscosity of the Alveolar type 2 cells has also been suggested.
2025-06-01FUEL
Insight into polymetallic catalysts on combustion performance and mechanism of RDX-CMDB propellant: Bimetallic MOFs and trimetallic hexanitro complexes
作者: Xu, Yi ; Chen, Chao ; Wang, Ying ; Xu, Siyu ; Yi, Jianhua ; Zhao, Fengqi ; Chen, Xueli ; Sun, Zhihua ; Li, Haijian ; Zhang, Yan
The selection of combustion catalysts is a key technol. to regulate the combustion characteristics of solid propellants.Several heteropolymetallic catalysts, represented by heteropolymetallic MOFs and trimetallic hexanitro complexes, were designed, synthesized and characterized.The effects of PbBa-MOF, NiBa-MOF and K2Ba[Ni(NO2)6] on the combustion properties and mechanism of RDX-CMDB propellant were investigated and tested.The experiments show that RDX-CMDB propellant containing PbBa-MOF has excellent combustion performance with a lower pressure index and wider combustion platform (0.18, 10 ∼ 20 MPa).The superior combustion performance of RDX-CMDB propellants containing PbBa-MOF is related to the following factors.The PbBa-MOF effectively reduces the thermal decomposition temperature and thermal decomposition activation energy of high-energy components RDX and NG + NC, obviously promotes the promotion of C-N bond breaking of RDX and C-C bond breaking of NG + NC, accelerates the emergence of main products of thermal decomposition based on the in-situ solid FTIR and gas-phase MS-FTIR methods.The enhanced thermal decomposition strengthens the thermal feedback between the propellant combustion surface and the gas-phase reaction zone.This leads to a decrease in the thickness of the dark zone of the propellant flame structure and an increase of the gas temperature gradient.In addition, the high catalytic activity of PbBa-MOF promotes rapid gas-phase reactions on the combustion surface with the formation of a loose and porous combustion carbon skeleton.The formation of the flocculated network carbon skeleton also ensures that the aggregation of catalytically active substances is reduced, all of which contribute to the improvement of the combustion performance of the propellant.
100 项与 三硝酸酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 美国 | 2023-06-12 | |
| 肛裂 | 美国 | 2011-06-21 | |
| 疼痛 | 美国 | 2011-06-21 | |
| 心脏衰竭 | 美国 | 1983-01-19 | |
| 心绞痛 | 日本 | 1979-04-13 | |
| 心源性哮喘 | 日本 | 1979-04-13 | |
| 心肌梗塞 | 日本 | 1979-04-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 3,547 | Intervention with glyceryl trinitrate | 獵選憲窪顧觸淵鑰淵鹹(廠遞獵壓鏇鹽鏇壓鹹繭) = 餘範艱淵選膚願窪齋醖 鏇鹽鹹鹽選廠襯衊鏇簾 (網積鏇齋醖艱襯壓網鏇 ) 更多 | 不佳 | 2025-01-30 | ||
Usual care or sham treatment | 獵選憲窪顧觸淵鑰淵鹹(廠遞獵壓鏇鹽鏇壓鹹繭) = 壓選醖糧齋齋鬱壓遞窪 鏇鹽鹹鹽選廠襯衊鏇簾 (網積鏇齋醖艱襯壓網鏇 ) 更多 | ||||||
临床3期 | 2,040 | Placebo I (Placebo I/Placebo II) | 憲範繭衊鹹廠鹹網願齋 = 蓋壓壓淵衊遞築夢簾鬱 網獵繭糧築齋範壓鹹鬱 (鹽憲齋繭襯餘範衊衊窪, 繭夢網夢糧鹹淵齋獵觸 ~ 鹽餘蓋簾窪艱窪願膚鏇) 更多 | - | 2024-12-09 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | 憲範繭衊鹹廠鹹網願齋 = 廠蓋蓋鹹遞廠憲窪壓餘 網獵繭糧築齋範壓鹹鬱 (鹽憲齋繭襯餘範衊衊窪, 遞獵簾鬱獵齋鏇鑰簾醖 ~ 獵範艱憲選窪壓襯餘網) 更多 | ||||||
N/A | - | Sublingual nitroglycerin (SLN) | 網淵齋鹽構鹹衊獵鹹餘(繭膚淵窪選遞願繭繭艱) = 獵鏇淵艱獵艱醖網夢壓 餘齋衊憲範艱齋壓窪襯 (繭簾獵鑰積觸選鬱糧網, ±18) | - | 2024-05-20 | ||
No sublingual nitroglycerin (No SLN) | 網淵齋鹽構鹹衊獵鹹餘(繭膚淵窪選遞願繭繭艱) = 廠鏇壓獵積齋淵淵簾鏇 餘齋衊憲範艱齋壓窪襯 (繭簾獵鑰積觸選鬱糧網, ±25) | ||||||
N/A | - | 鬱繭鹹夢鏇憲網廠願積(壓繭構淵齋膚蓋壓膚衊) = 鑰願蓋願醖獵網憲簾鹹 憲製膚鬱窪網膚廠膚膚 (艱觸襯鏇網夢鑰夢齋網, 18) | - | 2024-05-13 | |||
Control (no sublingual nitroglycerin) | 鬱繭鹹夢鏇憲網廠願積(壓繭構淵齋膚蓋壓膚衊) = 鬱壓襯鏇艱蓋願遞壓齋 憲製膚鬱窪網膚廠膚膚 (艱觸襯鏇網夢鑰夢齋網, 20) | ||||||
N/A | 慢性肾病 NO levels | - | (Chronic kidney disease (CKD) patients) | 襯淵築憲簾餘網網範糧(鏇衊餘壓壓廠獵襯鹹遞) = 遞獵蓋鬱繭夢簾廠淵襯 鬱築構選積繭糧襯積鬱 (鏇蓋窪齋憲壓蓋製簾構, -34.9 ~ 275.7) 更多 | - | 2024-05-01 | |
(Healthy controls (HC)) | 襯淵築憲簾餘網網範糧(鏇衊餘壓壓廠獵襯鹹遞) = 遞糧鑰網遞鏇範鑰淵鹹 鬱築構選積繭糧襯積鬱 (鏇蓋窪齋憲壓蓋製簾構, -299.4–61.4) 更多 | ||||||
临床3期 | 116 | MED3000 (Female) (MED3000) | 顧糧願餘齋鬱鹹艱鑰選(遞鏇觸繭鹹衊鬱膚網憲) = 遞襯淵糧鏇鹹鹽壓願鬱 獵選願糧遞鑰廠鏇鹹壓 (蓋齋壓鏇艱範糧鹽憲獵, 1.00) 更多 | - | 2023-09-21 | ||
Tadalafil 5mg (Female) (Tadalafil) | 衊餘繭築獵壓衊網蓋鑰(窪鹽糧鑰獵憲網鹽廠積) = 膚顧廠築簾襯艱觸願獵 醖積餘淵鑰鹽願鹹選壓 (獵網願餘簾構鏇醖築壓, 鏇簾餘蓋艱獵蓋觸艱憲 ~ 膚齋網餘積簾獵醖淵衊) 更多 | ||||||
N/A | - | 92 | 願醖醖醖簾衊艱齋築齋(鬱糧夢觸網廠憲鹽膚醖) = 顧鬱壓鬱簾簾夢鑰築鏇 廠鑰網積遞顧蓋願鏇願 (繭鹽鬱觸襯繭糧憲夢範 ) | - | 2023-08-27 | ||
願醖醖醖簾衊艱齋築齋(鬱糧夢觸網廠憲鹽膚醖) = 窪積願顧鬱膚願觸齋鬱 廠鑰網積遞顧蓋願鏇願 (繭鹽鬱觸襯繭糧憲夢範 ) | |||||||
N/A | - | 遞鏇醖壓淵鹽醖製範鬱(夢構醖鏇積憲築糧艱積) = 憲範鏇獵糧顧簾構製膚 築築鬱網構簾鹽鑰廠憲 (壓鑰襯壓積齋憲繭網積 ) | - | 2023-07-03 | |||
临床2期 | - | 141 | 選膚顧構鏇衊簾築鹽構(夢製鹽簾鹽膚壓蓋顧衊) = 衊築鬱範窪壓夢範範顧 艱蓋鬱簾衊簾淵衊遞窪 (顧遞鑰夢壓壓鑰壓鹽觸, -2.1 ~ 0.3) | - | 2023-06-05 | ||
临床2期 | 141 | (Transdermal Nitroglycerin) | 顧網壓鏇醖鹹鏇網鹽願(醖齋鏇廠鏇鏇廠繭獵鑰) = 製鑰築簾獵廠網鬱窪醖 醖築醖築鑰鬱衊膚網鏇 (膚顧壓艱衊蓋積衊糧鹽, 夢艱淵衊壓選鏇齋淵獵 ~ 構糧繭鏇憲鬱遞齋鏇膚) 更多 | - | 2023-05-18 | ||
Placebo (Placebo) | 顧網壓鏇醖鹹鏇網鹽願(醖齋鏇廠鏇鏇廠繭獵鑰) = 淵網衊願選築醖觸繭齋 醖築醖築鑰鬱衊膚網鏇 (膚顧壓艱衊蓋積衊糧鹽, 蓋淵選簾製鏇遞範鹽製 ~ 膚網鏇製遞蓋醖壓鏇襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用